Last reviewed · How we verify
NCT05011721: NeoFit
Digital Phenotyping in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
NA trial testing Activity tracker in Breast Cancer in 300 participants. Completed in 3 March 2025.
3 March 2025
Quick facts
| Lead sponsor | Institut Curie |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 300 |
| Start date | 20 September 2021 |
| Primary completion | 3 March 2025 |
| Estimated completion | 3 March 2025 |
| Sites | 3 locations across France |
Drugs / interventions tested
- Activity tracker
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Institut Curie — full company profile →
Who can join
Adults 18 to 70, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
NeoFit is a prospective, national, multicenter, single-arm open-label study. It will include a total of 300 participants under the age of 70 years treated with neoadjuvant chemotherapy for BC. Participants will receive a Withing Steel HR activity tracker, which they will be asked to wear 24 h per day for 12 months. The principal assessments will be performed at baseline, at the end of neoadjuvant chemotherapy and at 12 months. The investigators will evaluate clinical (e.g. toxicity, efficacy of chemotherapy), lifestyle, quality of life, fatigue, and physical activity parameters. All questionnaires will be completed on a REDCap form, via a secure internet link.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial.
Delrieu L, Hamy AS, Coussy F, Kassara A, et al · · 2022 · cited 3× · PMID 35509030 · DOI 10.1186/s12885-022-09608-y
Verify or expand the search:
- PubMed search for NCT05011721
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Activity tracker
Trials testing the same drug.
- NCT05794178 — Testing Responses of Young Adults to Intervention Messages for Promoting Physical Activity Trial · NA · recruiting
- NCT05634395 — Digital Phenotyping in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment · NA · active not recruiting
- NCT05583890 — A Case-control Study Comparing Glycaemic Control in Pancreatic Cancer Patients vs Healthy Matched Individuals. · completed
- NCT05388578 — The Stroke Box: a Patient-centered eHealth Approach for Improving Post-stroke Care. · unknown
- NCT03648957 — Lifestyle Counselling as Secondary Prevention in Patients With Minor Stroke and Transient Ischemic Attack · NA · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Institut Curie trials
Trials by the same sponsor.
- NCT07357948 — Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy · NA · not yet recruiting
- NCT07491380 — Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TD · NA · not yet recruiting
- NCT07193394 — Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer · Phase 2 · recruiting
- NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
- NCT06659705 — Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI) · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05011721 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Curie
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05011721.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing